37868-26-1

Basic information

• Product Name: 2-Indanylacetic acid
• Synonyms: INDAN-2-YL-ACETIC ACID;2-INDANYLACETIC ACID;2-(2,3-Dihydro-1H-inden-2-yl)acetic acid;2,3-dihydro-1H-inden-1-ylacetic acid;2,3-Dihydro-1H-inden-2-ylacetic acid;Indan-2-ylacetic acid 98%;1H-Indene-2-acetic acid, 2,3-dihydro-;2,3-Dihydro-1H-indene-2-acetic acid
• CAS NO: 37868-26-1
• Molecular Formula: C₁₁H₁₂O₂
• Molecular Weight: 176.21
• Mol File: 37868-26-1.mol
• Article Data: 6

Chemical Properties

• Melting Point: 91-93°C
• Boiling Point: 343.28°C at 760 mmHg
• Flash Point: 240.264°C
• Appearance: /
• Density: 1.169g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.568
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.70±0.10(Predicted)
• Water Solubility: Insoluble in water.
• BRN: 2616409
• CAS DataBase Reference: 2-Indanylacetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Indanylacetic acid(37868-26-1)
• EPA Substance Registry System: 2-Indanylacetic acid(37868-26-1)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36
• Hazardous Substances Data: 37868-26-1(Hazardous Substances Data)

Usage

Description

2-Indanylacetic acid, also known as 2-(1,2,3,4-tetrahydro-1-naphthalenyl)acetic acid, is an organic compound that serves as a crucial intermediate in the synthesis of various complex organic molecules. It is characterized by its unique pentacyclic structure, which makes it a valuable building block in the pharmaceutical and chemical industries.

Uses

Used in Pharmaceutical Industry:
2-Indanylacetic acid is used as a starting material for the synthesis of the pentacylic core of (+)-Salvileucalin, a natural product with potential biological activities. Its unique structure allows for the development of novel compounds with therapeutic applications, making it an essential component in the creation of new drugs and pharmaceuticals.

Synthesis Reference(s)

The Journal of Organic Chemistry, 26, p. 3555, 1961 DOI: 10.1021/jo01067a631

InChI:InChI=1/C11H12O2/c12-11(13)7-9-6-5-8-3-1-2-4-10(8)9/h1-4,9H,5-7H2,(H,12,13)

Upstream product

• 4471-33-4 3,3a,4,8b-tetrahydroindeno<1,2-b>furan-2-one 
• 53273-37-3 indan-2-yl-acetic acid methyl ester 
• 66658-02-4 acetic acid, (1,3-dihydro-2H-inden-2-ylidene)-, methyl ester 
• 615-13-4 2-indanone 
• 157406-12-7 (E)-2-(1-oxo-1,3-dihydro-2H-inden-2-ylidene)acetic acid 
• 83-33-0 inden-1-one 
• 114915-75-2 1-oxoindan-Δ^2,α-acetic acid 

Downstream Products

• 143356-09-6 ethyl 2-indanylacetate 
• 146737-93-1 2-(benzyloxycarbonylaminomethyl)indane 
• 146737-88-4 ethyl-trans-3-[2-[(4-chlorophenyl)sulfonylaminomethyl]indan-5-yl]acrylate 
• 146737-89-5 ethyl-3-[2-[(4-chlorophenyl)sulfonylaminomethyl]indan-5-yl]propionate 
• 4471-33-4 3,3a,4,8b-tetrahydroindeno<1,2-b>furan-2-one 
• 17496-14-9 2,3-dihydro-2-methyl-1H-inden-1-one 
• 351490-85-2 1,1-dimethyl-2-(indan-2-yl)ethylamine 
• 53273-37-3 indan-2-yl-acetic acid methyl ester 
• 772-28-1 2-(indan-2-yl)ethanol 

Relevant articles and documents

Strategic Approach to the Metamorphosis of γ-Lactones to NH γ-Lactams via Reductive Cleavage and C-H Amidation

A new approach has elaborated on the conversion of γ-lactones to the corresponding NH γ-lactams that can serve as γ-lactone bioisosteres. This approach consists of reductive C-O cleavage and an Ir-catalyzed C-H amidation, offering a powerful synthetic tool for accessing a wide range of valuable NH γ-lactam building blocks starting from γ-lactones. The synthetic utility was further demonstrated by the late-stage transformation of complex bioactive molecules and the asymmetric transformation.

Synthesis of the pentacylic core of (+)-salvileucalin B

A concise preparation of the prochiral pentacyclic core of (+)-salvileucalin B is presented. The key feature in the synthesis is the Cu-catalyzed intramolecular cyclopropanation of a symmetrical indane-derived α-diazo β-keto ester. This symmetry is carrie

TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS

The invention relates to novel tricyclic 1,2,4-triazine-1-oxides and novel tricyclic 1,2,4-triazine-1,4-dioxides of formula: (I); and to related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.